Abstract
Lenalidomide is an immunomodulatory drug (IMiD), a derivative of thalidomide used in the treatment of multiple myeloma. Stevens-Johnson syndrome (SJS) is a rare but life-t hreatening cutaneous adverse reaction, at a rate of 1.1 to 7.1 cases per million person-years, mortality rate between 1% to 3% and 10% to 70% when it is associated with TIN. Very few cases of Lenalidomide induced SJS has been reported. We describe a case of Stevens-Johnson syndrome induced by induction therapy lenalidomide-low dose Dexamethasone regimen in a 56 year-old male who underwent induction therapy for multiple myeloma.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Medical Research and Review
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
